Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy

Fabio Efficace, Fabio Stagno, Alessandra Iurlo, Massimo Breccia, Francesco Cottone, Massimiliano Bonifacio, Elisabetta Abruzzese, Fausto Castagnetti, Giovanni Caocci, Monica Crugnola, Isabella Capodanno, Bruno Martino, Mario Tiribelli, Andrea Patriarca, Antonella Gozzini, Patrizia Pregno, Susanne Saussele, Nicola Cascavilla, Claudio Fozza, Micaela BergamaschiGianni Binotto, Marco Vignetti, Gianantonio Rosti

Research output: Contribution to journalArticle

Abstract

There is paucity of evidence-based data on health-related quality of life (HRQOL) outcomes of chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs). We performed a multicenter propensity-matched case-control study to compare HRQOL of newly diagnosed CML patients treated with front-line dasatinib (cases) or imatinib (controls). Patient-reported HRQOL was assessed with the EORTC QLQ-C30 and the EORTC QLQ-CML24 questionnaires. The impact on daily life scale of the EORTC QLQ-CML24 was selected a priori in the protocol as the primary HRQOL scale for the comparative analysis. Overall, 323 CML patients were enrolled of whom 223 in therapy with imatinib and 100 in therapy with dasatinib. Patients treated with dasatinib reported better disease-specific HRQOL outcomes in impact on daily life (Δ = 8.72, 95% confidence interval [CI]: 3.17–14.27, p = 0.002), satisfaction with social life (Δ = 13.45, 95% CI: 5.82–21.08, p = 0.001), and symptom burden (Δ = 7.69, 95% CI: 3.42–11.96, p = 0.001). Analysis by age groups showed that, in patients aged 60 years and over, differences favoring dasatinib were negligible across several cancer generic and disease-specific HRQOL domains. Our findings provide novel comparative HRQOL data that extends knowledge on safety and efficacy of these two TKIs and may help to facilitate first-line treatment decisions.

Original languageEnglish
JournalLeukemia
DOIs
Publication statusAccepted/In press - Jan 1 2019

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Quality of Life
Confidence Intervals
Protein-Tyrosine Kinases
Therapeutics
Imatinib Mesylate
Dasatinib
Case-Control Studies
Age Groups
Safety
Neoplasms

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy. / Efficace, Fabio; Stagno, Fabio; Iurlo, Alessandra; Breccia, Massimo; Cottone, Francesco; Bonifacio, Massimiliano; Abruzzese, Elisabetta; Castagnetti, Fausto; Caocci, Giovanni; Crugnola, Monica; Capodanno, Isabella; Martino, Bruno; Tiribelli, Mario; Patriarca, Andrea; Gozzini, Antonella; Pregno, Patrizia; Saussele, Susanne; Cascavilla, Nicola; Fozza, Claudio; Bergamaschi, Micaela; Binotto, Gianni; Vignetti, Marco; Rosti, Gianantonio.

In: Leukemia, 01.01.2019.

Research output: Contribution to journalArticle

Efficace, F, Stagno, F, Iurlo, A, Breccia, M, Cottone, F, Bonifacio, M, Abruzzese, E, Castagnetti, F, Caocci, G, Crugnola, M, Capodanno, I, Martino, B, Tiribelli, M, Patriarca, A, Gozzini, A, Pregno, P, Saussele, S, Cascavilla, N, Fozza, C, Bergamaschi, M, Binotto, G, Vignetti, M & Rosti, G 2019, 'Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy', Leukemia. https://doi.org/10.1038/s41375-019-0563-0
Efficace, Fabio ; Stagno, Fabio ; Iurlo, Alessandra ; Breccia, Massimo ; Cottone, Francesco ; Bonifacio, Massimiliano ; Abruzzese, Elisabetta ; Castagnetti, Fausto ; Caocci, Giovanni ; Crugnola, Monica ; Capodanno, Isabella ; Martino, Bruno ; Tiribelli, Mario ; Patriarca, Andrea ; Gozzini, Antonella ; Pregno, Patrizia ; Saussele, Susanne ; Cascavilla, Nicola ; Fozza, Claudio ; Bergamaschi, Micaela ; Binotto, Gianni ; Vignetti, Marco ; Rosti, Gianantonio. / Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy. In: Leukemia. 2019.
@article{ffa23767a9924c0fbc49bd2beac98a2f,
title = "Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy",
abstract = "There is paucity of evidence-based data on health-related quality of life (HRQOL) outcomes of chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs). We performed a multicenter propensity-matched case-control study to compare HRQOL of newly diagnosed CML patients treated with front-line dasatinib (cases) or imatinib (controls). Patient-reported HRQOL was assessed with the EORTC QLQ-C30 and the EORTC QLQ-CML24 questionnaires. The impact on daily life scale of the EORTC QLQ-CML24 was selected a priori in the protocol as the primary HRQOL scale for the comparative analysis. Overall, 323 CML patients were enrolled of whom 223 in therapy with imatinib and 100 in therapy with dasatinib. Patients treated with dasatinib reported better disease-specific HRQOL outcomes in impact on daily life (Δ = 8.72, 95{\%} confidence interval [CI]: 3.17–14.27, p = 0.002), satisfaction with social life (Δ = 13.45, 95{\%} CI: 5.82–21.08, p = 0.001), and symptom burden (Δ = 7.69, 95{\%} CI: 3.42–11.96, p = 0.001). Analysis by age groups showed that, in patients aged 60 years and over, differences favoring dasatinib were negligible across several cancer generic and disease-specific HRQOL domains. Our findings provide novel comparative HRQOL data that extends knowledge on safety and efficacy of these two TKIs and may help to facilitate first-line treatment decisions.",
author = "Fabio Efficace and Fabio Stagno and Alessandra Iurlo and Massimo Breccia and Francesco Cottone and Massimiliano Bonifacio and Elisabetta Abruzzese and Fausto Castagnetti and Giovanni Caocci and Monica Crugnola and Isabella Capodanno and Bruno Martino and Mario Tiribelli and Andrea Patriarca and Antonella Gozzini and Patrizia Pregno and Susanne Saussele and Nicola Cascavilla and Claudio Fozza and Micaela Bergamaschi and Gianni Binotto and Marco Vignetti and Gianantonio Rosti",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41375-019-0563-0",
language = "English",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy

AU - Efficace, Fabio

AU - Stagno, Fabio

AU - Iurlo, Alessandra

AU - Breccia, Massimo

AU - Cottone, Francesco

AU - Bonifacio, Massimiliano

AU - Abruzzese, Elisabetta

AU - Castagnetti, Fausto

AU - Caocci, Giovanni

AU - Crugnola, Monica

AU - Capodanno, Isabella

AU - Martino, Bruno

AU - Tiribelli, Mario

AU - Patriarca, Andrea

AU - Gozzini, Antonella

AU - Pregno, Patrizia

AU - Saussele, Susanne

AU - Cascavilla, Nicola

AU - Fozza, Claudio

AU - Bergamaschi, Micaela

AU - Binotto, Gianni

AU - Vignetti, Marco

AU - Rosti, Gianantonio

PY - 2019/1/1

Y1 - 2019/1/1

N2 - There is paucity of evidence-based data on health-related quality of life (HRQOL) outcomes of chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs). We performed a multicenter propensity-matched case-control study to compare HRQOL of newly diagnosed CML patients treated with front-line dasatinib (cases) or imatinib (controls). Patient-reported HRQOL was assessed with the EORTC QLQ-C30 and the EORTC QLQ-CML24 questionnaires. The impact on daily life scale of the EORTC QLQ-CML24 was selected a priori in the protocol as the primary HRQOL scale for the comparative analysis. Overall, 323 CML patients were enrolled of whom 223 in therapy with imatinib and 100 in therapy with dasatinib. Patients treated with dasatinib reported better disease-specific HRQOL outcomes in impact on daily life (Δ = 8.72, 95% confidence interval [CI]: 3.17–14.27, p = 0.002), satisfaction with social life (Δ = 13.45, 95% CI: 5.82–21.08, p = 0.001), and symptom burden (Δ = 7.69, 95% CI: 3.42–11.96, p = 0.001). Analysis by age groups showed that, in patients aged 60 years and over, differences favoring dasatinib were negligible across several cancer generic and disease-specific HRQOL domains. Our findings provide novel comparative HRQOL data that extends knowledge on safety and efficacy of these two TKIs and may help to facilitate first-line treatment decisions.

AB - There is paucity of evidence-based data on health-related quality of life (HRQOL) outcomes of chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs). We performed a multicenter propensity-matched case-control study to compare HRQOL of newly diagnosed CML patients treated with front-line dasatinib (cases) or imatinib (controls). Patient-reported HRQOL was assessed with the EORTC QLQ-C30 and the EORTC QLQ-CML24 questionnaires. The impact on daily life scale of the EORTC QLQ-CML24 was selected a priori in the protocol as the primary HRQOL scale for the comparative analysis. Overall, 323 CML patients were enrolled of whom 223 in therapy with imatinib and 100 in therapy with dasatinib. Patients treated with dasatinib reported better disease-specific HRQOL outcomes in impact on daily life (Δ = 8.72, 95% confidence interval [CI]: 3.17–14.27, p = 0.002), satisfaction with social life (Δ = 13.45, 95% CI: 5.82–21.08, p = 0.001), and symptom burden (Δ = 7.69, 95% CI: 3.42–11.96, p = 0.001). Analysis by age groups showed that, in patients aged 60 years and over, differences favoring dasatinib were negligible across several cancer generic and disease-specific HRQOL domains. Our findings provide novel comparative HRQOL data that extends knowledge on safety and efficacy of these two TKIs and may help to facilitate first-line treatment decisions.

UR - http://www.scopus.com/inward/record.url?scp=85072203827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072203827&partnerID=8YFLogxK

U2 - 10.1038/s41375-019-0563-0

DO - 10.1038/s41375-019-0563-0

M3 - Article

C2 - 31477798

AN - SCOPUS:85072203827

JO - Leukemia

JF - Leukemia

SN - 0887-6924

ER -